Zacks Investment Research upgraded shares of InVivo Therapeutics (NVIV) from NEUTRAL to OUTPERFORM on January 21, 2015, with a target price of $3.25.
On January 21, 2015, InVivo Therapeutics (NVIV) provided an update on the status of the first patient enrolled in the company's ongoing pilot study of its investigational Neuro-Spinal Scaffold (NSS) for the treatment of acute spinal cord injury. The primary safety endpoint will be assessed again at six months, but things look to have gone well with respect to the key gating-factor to moving forward with enrolling more patients in the study. However, what was unexpected so soon after the surgery was the functional recovery seen to date. According to InVivo's press release, the subject has progressed from a complete AIS-A injury (pre-surgery) to an incomplete AIS-C injury with motor, sensory, bowel, and bladder function improvements. We are buyers of the stock. Our target is $3.25 per share.
To get a free copy of the research report on InVivo Therapeutics (NVIV),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment